A gene that’s associated with an autoimmune form of hair loss could be exploited to improve cancer immunotherapy, suggests a new mouse study by Columbia University Irving Medical Center (CUIMC) researchers.
Researchers have designed nanoparticles that can be attached to T-cells and release T-cell-stimulating molecules called cytokines, that activate T-cells to attack nearby tumour cells.
Researchers have come up with a tool that offers a means of control over engineered cells, and it comes from a seemingly unlikely source — the hepatitis C genome.
Researchers have identified a new subtype of prostate cancer that occurs in about 7% of patients with advanced disease. This subset of tumours was responsive to immunotherapy treatment.
Researchers have discovered that tumour cells reprogram metabolic pathways to gain control over a type of immune cell that allows cancer growth.
A patient with metastatic breast cancer has made a dramatic recovery after receiving a personalised therapy using her own cells.